Merck KGaA (Merck) has sufficient funds and is planning to go for acquisitions in pharmaceuticals and chemical industries, reported Reuters, quoting a German newspaper. Karl-Ludwig Kley, chief executive
Sinovac Biotech (Sinovac) has filed an application with China’s State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71
Compugen has reported the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 is a membrane splice variant of CD55, a known
An independent Safety Monitoring Board (SMB) has completed the third scheduled safety analysis for Vical’s phase 3 AIMM trial of Allovectin-7 in patients with metastatic melanoma and recommended
Emerald BioStructures (formerly deCODE biostructures) has reported a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD)
Rigel Pharmaceuticals (Rigel) has received a milestone payment from Daiichi Sankyo as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which
Eli Lilly and Kowa Pharmaceuticals America (Kowa) have entered into a co-promotion agreement in the US to commercialise Livalo (pitavastatin). Lilly and Kowa have also entered into a
Forest Laboratories (Forest) has entered into an agreement to acquire additional rights to NXL 104. This amends the terms of its prior agreement with Novexel covering the combination
The FDA has issued a complete response letter regarding Pfizer’s New Drug Application (NDA) for Lyrica (pregabalin) capsules CV, as a monotherapy treatment for generalised anxiety disorder (GAD).
Merck & Co has decided to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis, being developed under its research collaboration with Arena Pharmaceuticals (Arena).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.